153 related articles for article (PubMed ID: 2944573)
21. Treatment of stage D2 prostatic cancer refractory to or relapsed following castration plus oestrogens. Comparison of aminoglutethimide plus hydrocortisone with medroxyprogesterone acetate plus hydrocortisone.
Bezwoda WR
Br J Urol; 1990 Aug; 66(2):196-201. PubMed ID: 2143960
[TBL] [Abstract][Full Text] [Related]
22. High dose medroxyprogesterone acetate (MPA) treatment in metastatic carcinoma of the breast: a dose-response evaluation.
Cuna GR; Calciati A; Strada MR; Bumma C; Campio L
Tumori; 1978 Apr; 64(2):143-9. PubMed ID: 354147
[TBL] [Abstract][Full Text] [Related]
23. Medroxyprogesterone acetate at very high doses in postmenopausal advanced breast cancer patients.
Pannuti F; Longhi A; Martoni A; Piana E; Baroni M
Chemioterapia; 1987 Dec; 6(6):396-8. PubMed ID: 2963702
[TBL] [Abstract][Full Text] [Related]
24. Protective effect of high-dose medroxyprogesterone acetate (HD-MPA) on hematological toxicity induced by chemotherapy for advanced solid tumors: a multicentric controlled clinical trial. MPA-Hematology Italian Cooperative Group.
Chemioterapia; 1986 Apr; 5(2):134-9. PubMed ID: 2871945
[TBL] [Abstract][Full Text] [Related]
25. Oral versus im administration of high-dose medroxyprogesterone acetate in pretreated patients with advanced breast cancer.
Beex L; Burghouts J; van Turnhout J; Breed W; Hillen H; Holdrinet A; Boetius G; Hoogendoorn G; Doesburg W; Verhulst M
Cancer Treat Rep; 1987 Dec; 71(12):1151-6. PubMed ID: 3690524
[TBL] [Abstract][Full Text] [Related]
26. Prospective randomized study of aminoglutethimide (AG) versus medroxyprogesterone acetate (MPA) versus AG+MPA in generalized breast cancer.
Samonis G; Margioris AN; Bafaloukos D; Razis DV
Oncology; 1994; 51(5):411-5. PubMed ID: 8052481
[TBL] [Abstract][Full Text] [Related]
27. [Mitomycin C and high-dosage medroxyprogesterone acetate in the therapy of metastasizing breast cancer. Results of a phase II study of the Workshop for Internal Oncology of the German Cancer Association].
Bartsch HH; Blossey HC; Nagel GA
Onkologie; 1982 Oct; 5(5):249-57. PubMed ID: 6218456
[TBL] [Abstract][Full Text] [Related]
28. [Therapeutic effects of medroxyprogesterone acetate in recurrent or advanced breast cancer].
Yoshida M; Murai H; Miura S
Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):516-23. PubMed ID: 3159345
[TBL] [Abstract][Full Text] [Related]
29. Oral high-dose medroxyprogesterone acetate versus tamoxifen. A randomized crossover trial in postmenopausal patients with advanced breast cancer.
van Veelen H; Willemse PH; Tjabbes T; Schweitzer MJ; Sleijfer DT
Cancer; 1986 Jul; 58(1):7-13. PubMed ID: 2939943
[TBL] [Abstract][Full Text] [Related]
30. Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study.
Muss HB; Case LD; Atkins JN; Bearden JD; Cooper MR; Cruz JM; Jackson DV; O'Rourke MA; Pavy MD; Powell BL
J Clin Oncol; 1994 Aug; 12(8):1630-8. PubMed ID: 8040675
[TBL] [Abstract][Full Text] [Related]
31. Randomized trial of low- versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer.
Cavalli F; Goldhirsch A; Jungi F; Martz G; MermillodB ; Alberto P
J Clin Oncol; 1984 May; 2(5):414-9. PubMed ID: 6233398
[TBL] [Abstract][Full Text] [Related]
32. Sequential alternating medroxyprogesterone acetate and epirubicin in the treatment of advanced breast cancer.
Smith JA; Green MD; Russell IS; Collins JP
Aust N Z J Surg; 1989 Nov; 59(11):869-72. PubMed ID: 2530970
[TBL] [Abstract][Full Text] [Related]
33. Oral versus intramuscular high-dose medroxyprogesterone acetate (HD-MPA) in advanced breast cancer. A randomized study of the Belgian Society of Medical Oncology.
Paridaens R; Becquart D; Michel J; Vanderlinden B; Longueville J; Majois F; Beauduin M; Focan C; Wildiers J; Bernheim J
Anticancer Res; 1986; 6(5):1089-94. PubMed ID: 2948441
[TBL] [Abstract][Full Text] [Related]
34. High-dose medroxyprogesterone acetate in combination with vindesine in advanced breast cancer.
Falkson HC; Falkson G
Eur J Cancer Clin Oncol; 1986 Dec; 22(12):1511-4. PubMed ID: 2954823
[TBL] [Abstract][Full Text] [Related]
35. High-dose medroxyprogesterone acetate (MPA) treatment in advanced breast cancer. A review.
Ganzina F
Tumori; 1979 Oct; 65(5):563-85. PubMed ID: 390798
[TBL] [Abstract][Full Text] [Related]
36. Randomized trial comparing aminoglutethimide with high-dose medroxyprogesterone acetate in therapy for advanced breast carcinoma.
Canney PA; Priestman TJ; Griffiths T; Latief TN; Mould JJ; Spooner D
J Natl Cancer Inst; 1988 Sep; 80(14):1147-51. PubMed ID: 2970555
[TBL] [Abstract][Full Text] [Related]
37. Aminoglutethimide as second line therapy in advanced breast cancer.
Elomaa I; Blomqvist C; Rissanen P
Breast Cancer Res Treat; 1986; 7 Suppl():S51-4. PubMed ID: 3017481
[TBL] [Abstract][Full Text] [Related]
38. Treatment of breast cancer with medroxyprogesterone acetate.
Muggia FM; Cassieth PA; Ochoa M; Flatow FA; Gellhorn A; Hyman GA
Ann Intern Med; 1968 Feb; 68(2):328-37. PubMed ID: 4306126
[TBL] [Abstract][Full Text] [Related]
39. Aminoglutethimide in the treatment of premenopausal patients with metastatic breast cancer.
Wander HE; Blossey HC; Nagel GA
Eur J Cancer Clin Oncol; 1986 Nov; 22(11):1371-4. PubMed ID: 3830219
[TBL] [Abstract][Full Text] [Related]
40. A phase II study of high-dose medroxyprogesterone acetate in advanced breast cancer.
Falkson G; Falkson HC
Cancer Chemother Pharmacol; 1983; 11(1):16-8. PubMed ID: 6224603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
